<DOC>
	<DOCNO>NCT02146664</DOCNO>
	<brief_summary>This prospective , randomize , double-blind , double-dummy , control study DLBS1033 management acute non-ST elevation myocardial infarction ( NSTEMI ) without early coronary revascularization . It hypothesize combination DLBS1033 aspirin clopidogrel result great reduction infarct size comparison aspirin clopidogrel alone .</brief_summary>
	<brief_title>DLBS1033 Acute NSTEMI Without Early Coronary Revascularization</brief_title>
	<detailed_description>After diagnose NSTEMI , patient hospitalize give medication accord standard management acute NSTEMI , include anticoagulant low molecular weight heparin . Eligible subject randomize receive either DLBS1033 dose 490 mg three time daily placebo addition clopidogrel 75 mg daily aspirin 160 mg daily 8-week course therapy . Afterwards , administration DLBS1033 placebo stop , dual antiplatelet therapy ( aspirin clopidogrel ) remain another 16 week dose regimen previous . Clinical laboratory examination evaluate investigational drug 's efficacy safety perform baseline , week 4 , week 8 , week 24 . To guard safety study subject , haemostasis parameter , hematology parameter , CRUSADE bleed score evaluate every two-week-interval first eight week treatment .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<criteria>Men woman 3075 year age . Evidence acute nonST elevation myocardial infarction ( NSTEMI ) screening , confirm follow : ECG transient STsegment deviation/depression ( ≥ 1 mm ) prominent Twave inversion , multiple precordial lead ; Positive plasma biomarkers myocardial necrosis : cardiac troponin I ( cTnI ) ; Clinical symptom chest discomfort/pain anginal equivalent ( dyspnea , diaphoresis , excessive vomit diabetic patient arm jaw pain ) . High risk subject , define Thrombolysis Myocardial Infarction ( TIMI ) score ≥ 4 Subjects refuse undergo reperfusion therapy , coronary arterybypass surgery ( CABG ) percutaneous coronary intervention ( PCI ) within next six month . Therapy study medication start within 7 day first presentation hospital . Able take oral medication . For female childbearing potential : pregnancy , breastfeeding , intention become pregnant . ECG presentation STEMI . History hemorrhagic stroke within last 3 month . Patients seizure onset stroke regular medication seizure/epilepsy . History serious head injury within last 3 month . History major surgery within last 3 month . Ongoing long term need oral anticoagulant , antiplatelets , fibrinolytic , antithrombotic agent , study medication . Having implant pacemaker cardiac resynchronization therapy ( CRT ) cardiac resynchronization therapy defibrillator ( CRTD ) . Clinically significant arrhythmia atrioventricular conduction block great first degree . Acute chronic heart failure define New York Heart Association ( NYHA ) classification functional Class IV . Known severe LV dysfunction ( EF ≤ 40 EDD &gt; 55 mm ) . Inadequate liver function : ALT &gt; 3 time upper limit normal ( ULN ) . Inadequate renal function : serum creatinine ≥ 1.5 time upper limit normal ( ULN ) . Uncontrolled hypertension ( SBP &gt; 185 mmHg DBP &gt; 110 mmHg ) . Random plasma glucose ≥ 180 mg/dL HbA1c ≥ 7.0 % Screening . Moderate high risk bleeding , define CRUSADE bleed score &gt; 30 . Known suspect allergy study medication use study , include lumbrokinase product . Prior experience DLBS1033 oral lumbrokinase product . Clinical evidence malignancy survival period &lt; 1 year . Any disease judge investigator could interfere trial participation trial evaluation . Enrolled interventional protocol within 30 day prior Screening .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Acute NSTEMI</keyword>
	<keyword>DLBS1033</keyword>
	<keyword>SPECT</keyword>
	<keyword>Infarct size</keyword>
	<keyword>Left ventricular function</keyword>
</DOC>